Centaurus Financial’s iBio IBIO Stock Holding History

Centaurus Financial’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-94	Closed	-$49K	–	848
2020 Q4	$49K	Buy	+94	New	+$76.6K	0.01%	768

Other funds holding IBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Centaurus Financial's IBIO Position: Q1 2021 in Review

Centaurus Financial sold out of iBio (IBIO) in Q1 2021, closing a stake of 94 shares — an estimated $49K sold.

Centaurus Financial first reported a position in IBIO in Q4 2020 and held it in 1 quarter. The position peaked at $49K in Q4 2020. 91 funds tracked by Wall St. Rank hold IBIO as of Q1 2021.

Centaurus Financial reported no remaining iBio position as of Q1 2021 after selling out during the quarter.
Centaurus Financial sold 94 iBio shares in Q1 2021, an estimated $49K.
Centaurus Financial first reported a position in iBio in Q4 2020 and held it in 1 quarter.
Centaurus Financial's iBio position peaked at $49K in Q4 2020.
91 funds tracked by Wall St. Rank held iBio as of Q1 2021.

Based on Centaurus Financial's 13F filing for Q1 2021, filed 30 Apr 2021.